ATXS Logo

Astria Therapeutics, Inc. (ATXS) 

NASDAQ$6.45
Market Cap
$364M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
468 of 924
Rank in Industry
275 of 527

ATXS Insider Trading Activity

ATXS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$135,9391100

Related Transactions

Morabito ChristopherChief Medical Officer0$01$135,939$-135,939

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, â€¦

Insider Activity of Astria Therapeutics, Inc.

Over the last 12 months, insiders at Astria Therapeutics, Inc. have bought $0 and sold $135,939 worth of Astria Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Astria Therapeutics, Inc. have bought $17.2M and sold $123,652 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,481,350 shares for transaction amount of $30M was made by PERCEPTIVE ADVISORS LLC (director) on 2024‑02‑01.

List of Insider Buy and Sell Transactions, Astria Therapeutics, Inc.

2024-04-01SaleMorabito ChristopherChief Medical Officer
10,000
0.0183%
$13.59$135,939-27.83%
2024-02-01PurchasePERCEPTIVE ADVISORS LLCdirector
2.48M
5.6893%
$12.09$30M-19.99%
2024-01-29SaleMorabito ChristopherChief Medical Officer
9,200
0.0208%
$11.15$102,552-8.93%
2024-01-26SaleMorabito ChristopherChief Medical Officer
800
0.0022%
$11.02$8,812+2.98%
2023-12-21PurchasePERCEPTIVE ADVISORS LLCdirector
740,000
2.0257%
$6.20$4.59M+77.37%
2023-10-16PurchasePERCEPTIVE ADVISORS LLCdirector
1.07M
3.9128%
$6.51$7M+56.68%
2022-12-19PurchasePERCEPTIVE ADVISORS LLCdirector
908,265
6.1619%
$11.01$10M-11.17%
2021-11-19PurchaseKomjathy AndrewChief Commercial Officer
100
0.0008%
$6.70$670-6.97%
2015-06-30PurchaseSVLSF V, LLC10 percent owner
391,090
2.5125%
$12.00$4.69M-41.69%
2015-06-30PurchaseGALAKATOS NICHOLAS
376,695
2.4201%
$12.00$4.52M-41.69%
2015-06-30PurchaseClarus Lifesciences II, L.P.10 percent owner
376,695
2.4201%
$12.00$4.52M-41.69%
2015-06-30PurchaseMedImmune Ventures, Inc.10 percent owner
223,439
1.4355%
$12.00$2.68M-41.69%
2015-06-30PurchaseLaufer Ron
223,439
1.4355%
$12.00$2.68M-41.69%
2015-06-30PurchaseGeorge Jeandirector
258,776
1.6625%
$12.00$3.11M-41.69%
Total: 14
*Gray background shows transactions not older than one year

Insider Historical Profitability

19.18%
PERCEPTIVE ADVISORS LLCdirector
4873721
8.6361%
$31.44M40+25.72%
SVLSF V, LLC10 percent owner
2798528
4.9589%
$18.05M10
GALAKATOS NICHOLAS
2752488
4.8773%
$17.75M10
Clarus Lifesciences II, L.P.10 percent owner
2752488
4.8773%
$17.75M10
MedImmune Ventures, Inc.10 percent owner
1632652
2.893%
$10.53M10

Historical Insider Profitability vs. Competitors

$109,415,500
33
18.13%
$353.41M
$41,446,394
27
12.91%
$340.18M
$14,865,077
18
-28.56%
$389.16M
$276,750,010
16
-7.95%
$385.21M
$3,232,510
15
-2.42%
$328.58M

ATXS Institutional Investors: Active Positions

Increased Positions70+70.71%6M+9.95%
Decreased Positions40-40.4%4M-6.24%
New Positions27New3MNew
Sold Out Positions17Sold Out1MSold Out
Total Postitions129+30.3%59M+3.71%

ATXS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$50,385.0013.97%7.82M+1,454+0.02%2024-12-31
Perceptive Advisors Llc$41,766.0011.58%6.49M00%2024-12-31
Ra Capital Management, L.P.$32,878.009.12%5.11M00%2024-12-31
Vestal Point Capital, Lp$26,919.007.46%4.18M+180,000+4.5%2024-12-31
Blackrock, Inc.$25,096.006.96%3.9M+397,387+11.36%2024-12-31
Fairmount Funds Management Llc$22,889.006.35%3.55M00%2024-12-31
Fcpm Iii Services B.V.$18,499.005.13%2.87M+3MNew2024-12-31
Tcg Crossover Management, Llc$17,786.004.93%2.76M00%2024-12-31
Vanguard Group Inc$17,242.004.78%2.68M+41,833+1.59%2024-12-31
Vr Adviser, Llc$15,825.004.39%2.46M-1M-28.95%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.